Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales

Executive Summary

Novartis AG unit Sandoz Inc. won US approval of its biosimilar Erelzi, which is referenced on Amgen's tumor necrosis factor blocker Enbrel (etanercept). The product, however, currently is caught in a patent dispute, although a recent stipulation has provided some hope for a smoother path through the legal jungle than other biosimilars may face.

Advertisement

Related Content

As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Pfizer/Celltrion Prep For October Inflectra Launch
Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Nixed Remicade Patent Clears Way For Pfizer/Celltrion Biosimilar Launch
Sandoz Climbs 'Pyramid' To Reach Biosimilar Success
FDA: Biosimilar Labeling Should Rely On Innovator Data
Lawsuit: Sandoz Copycat Piggybacks Enbrel, Ducks Duties
1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel